Spot Trading’s Rigel Pharmaceuticals RIGL Stock Holding History

Spot Trading’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,000	Closed	-$32K	–	4199
2015 Q2	$32K	Buy	+1,000	New	+$38.2K	﹤0.01%	3379

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Spot Trading's RIGL Position: Q3 2015 in Review

Spot Trading sold out of Rigel Pharmaceuticals (RIGL) in Q3 2015, closing a stake of 249 shares — an estimated $8K sold.

Spot Trading first reported a position in RIGL in Q2 2013 and held it in 3 quarters. The position peaked at $61K in Q2 2013. 122 funds tracked by Wall St. Rank hold RIGL as of Q3 2015.

Spot Trading reported no remaining Rigel Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Spot Trading sold 249 Rigel Pharmaceuticals shares in Q3 2015, an estimated $8K.
Spot Trading first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 3 quarters.
Spot Trading's Rigel Pharmaceuticals position peaked at $61K in Q2 2013.
122 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2015.

Based on Spot Trading's 13F filing for Q3 2015, filed 3 Nov 2015.